From clinical trial site to one of the few institutions in the country authorized to deliver all available FDA-approved CAR T-cell therapies, Fox Chase Cancer Center describes its successful evolution and identifies effective practices to help community cancer centers surmount the financial barriers to therapy as well as build strong referral networks with institutions offering cellular therapies.

In the third in a series of multidisciplinary consensus-building roundtables, ACCC and its partners explored ways to bridge the gap between community oncology programs and authorized treatment centers offering CAR T for patients with multiple myeloma.

In a recent conversation with ACCC, Kevan Simms, MBA, PMP, Assistant Vice President of Precision Medicine at Ochsner Health, shared how his organization is building a scalable stewardship model that not only improves current oncology care but also prepares for the future.

In a recent conversation with ACCC, DiMe Associate Program Director Ian Miller discussed what responsible AI adoption looks like in practice, particularly for organizations early in their AI journey and seeking clearer guidance on how to evaluate, prioritize, and implement these tools.

In the recent NCCN policy summit "Health Literacy in the Cancer Care Digital Age," speakers and panelists discussed how best to communicate with patients and foster the responsible use of emerging technologies, with a strong focus on shared decision-making.
